IMF TV

From our weekly series “Ask Dr. Durie” to comprehensive news from key cancer medical conferences around the world, IMF-TV is your all-access ticket to critical myeloma research, patient education and guidance. Check back often for regularly updated content. 

Feb
15
Should patients with light chain myeloma be more wary of disease outcomes than those with other types of myeloma?
In this week’s video, Dr. Brian G.M. Durie explains that the underlying biology of light chain myeloma is very similar to IgG or IgA myeloma.
Feb
08
How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ?
In this week’s video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma — the CESAR trial and the CENTAURUS trial. BOTTOM LINE: The IMF’s Black Swan Research(...)
Feb
01
Can you explain the results of the IFM 2009 trial?
In this week’s video, Dr. Brian G.M. Durie explains the somewhat confusing results of the IFM 2009 trial. BOTTOM LINE: ​ With longer follow-up, the IFM 2009 trial may be able to demonstrate longer(...)
Jan
25
What is MRD, or Minimal Residual Disease?
In this week’s video, Dr. Brian G.M. Durie defines minimal residual disease (MRD) and explains how MRD-testing can be used for ongoing monitoring. BOTTOM LINE: ​ As it may one day be a guide for(...)
Jan
18
Should a myeloma patient take supplements such as selenium?
In this week’s video, Dr. Brian G.M. Durie explains why myeloma patients should discuss the use of supplements with their doctors. BOTTOM LINE: ​ Stop unnecessary supplements that may have harmful(...)
Jan
11
Best of ASH 2017
Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma(...)